Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will be in a listen-only mode.
SALT LAKE CITY , March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during t...
SALT LAKE CITY , March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the s...
The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV Awareness Day, in Baroda, India SALT LAKE CITY , March 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the...
The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component SALT LAKE CITY , Feb. 21, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, following a collaborative...
SALT LAKE CITY , Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be participating in Nasdaq's Live from MarketSite broadcast at the Silicon Slopes Summit 2025 on January 14, 2025. Live from MarketSite is ...
New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers® in-house. Attendees of new ribbon-cutting event expected to include representatives from NGOs and government leaders SALT LAKE CITY , Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platfo...
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations. Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Jade Montgomery - H.C.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.